Kornimate/medical-research-clean huggingface dataset:
follicular activation in poor responders

Conditions: Infertility

Summary: this study aims to assess whether activation of primordial follicles through ovarian cortex fragmentation may increase the number of antral follicles present in the ovary of patients with diminished ovarian reserve. secondary outcomes include number of oocytes retrieved and pregnancy rates after ivf. hypothesis; evaluate whether the proposed intervention increases the pool of antral follicles (potentially stimulable ones).

controlled, randomized, assessor-blind clinical trial. thirty-six patients of la fe university hospital (valencia), previously confirmed as poor responders according to the european society of human reproduction and embryology (eshre) criteria, will be randomized to two treatment arms: * arm 1 (control): no intervention. * arm 2 (intervention): ovarian cortex extraction by unilateral laparoscopic biopsy and ovarian tissue fragmentation in aliquots of 1 mm2. these fragments will be grafted under the ovarian cortex and meso-ovarium ipsilateraly. subsequently the number of antral follicles in both intervention groups will be compared and also will be the number of antral follicles in the native ovary and the grafted one in each of the patients. patients will receive a standard ivf treatment for poor responders according to the protocols of the assisted reproduction unit of la fe university hospital. the final aim is to assess the pregnancy rate in both groups, as well as parameters related to the reproduction technique when required.

Eligibility criteria:
inclusion criteria (must meet one): * at least two episodes of poor ovarian response (≤ 3 oocytes retrieved with a standard protocol). * a previous ivf cycle with ≤ 3 oocytes (following a standard stimulation protocol) and presence of an abnormal ovarian reserve test (antral follicle count of ≤ 5 or antimüllerian hormone ≤ 5pm). exclusion criteria (must not meet any): * patients under 18 or over 40 years. * clinical signs of endometriosis. * previous ovarian surgery. * genital tract malformations. * anovulatory patient (defined by the presence of irregular cycles and serum progesterone ≤ 10 ng / ml on cycle day 21). * partner with severe male factor: severe oligoasthenozoospermia, oligoasthenoteratozoospermia and azoospermia. * all those patients who do not voluntarily give their express written consent.

Keywords: poor ovarian response salvador/warts/hippo pathway follicular activation poor ovarian reserve
topiramate in the treatment of post traumatic stress disorder (ptsd)

Conditions: PTSD

Summary: to study the potential therapeutic effects of topiramate (topamax) in the treatment of ptsd.

this is a twelve-week randomized, double blind, placebo controlled trial of topiramate for 40 patients with ptsd. diagnoses are made by structured clinical interview for dsm-iv (scid). symptom severity is measured with the clinician administered ptsd scale (caps), davidson trauma scale (dts), treatment outcome ptsd (top-8), clinical global impressions (cgi), and the hamilton rating scales for depression and anxiety (ham-d and ham-a). the clinician administered ptsd scale (caps) is the primary outcome measure. subjects will read and sign informed consent prior to beginning any study procedures. subjects who meet inclusion/exclusion criteria will be randomized 1:1 (topiramate : placebo) to study medication. study medication is initiated at one tablet daily (25mg topiramate or placebo) and medication will be increased by 25-100mg (1 tablet) increments every 7 days, as tolerated, until a maximum benefit is achieved, not to exceed 400mg/day. patients will be seen every week up until visit 4, and then will be seen every two weeks for the remainder of the study for assessment of efficacy and side effects.

Eligibility criteria:
inclusion criteria: * diagnosis of ptsd dsm-iv criteria * no substance abuse/dependence for the previous 2 months (except for nicotine and caffeine) * free of psychotropic medication, for 2 weeks (except 6 weeks for fluoxetine) * normal physical and laboratory examination (lab profile listed below) * negative urine screen for drugs of abuse * women of childbearing potential must be using nonpharmacologic medically approved methods of birth control * signed informed consent * male or female, any race or ethic origin exclusion criteria: * lifetime history of bipolar, psychotic, or cognitive disorders * suicidal, homicidal, or psychotic * diagnosis of bulimia or anorexia nervosa * history of sensitivity to topiramate * general medical conditions or ongoing treatment that contraindicate the use of topiramate, such as seizure disorder or use of mao inhibitors. * women planning to become pregnant or breastfeed during the study

Keywords: topiramate ptsd posttraumatic stress disorder topamax
a pilot study to evaluate the effects of subcutaneously administered recombinant human granulocyte-macrophage colony stimulating factor in pediatric hiv-infected patients with neutropenia secondary to azidothymidine

Conditions: HIV Infections; Cytopenias

Summary: to assess the safety and efficacy of subcutaneous sargramostim ( granulocyte-macrophage colony-stimulating factor; gm-csf ) in increasing and maintaining the granulocyte count in hiv-infected children who have developed granulocytopenia as a result of continuous intravenous ( civ ) zidovudine ( azt ). to assess the short-term and long-term effects of concomitant gm-csf on other hematologic parameters. to assess the potential therapeutic benefit of concomitant gm-csf and azt on the natural history of hiv infection and associated infectious complications.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * zidovudine (azt) on niaid 86-c-175. patients must have: * diagnosis of perinatal or transfusion acquired aids or aids related complex. * granulocytopenia (\< or = to 800 cells/mm3) associated with the administration of azt on protocol niaid 86-c-175. * life expectancy \> 3 months. * functioning indwelling central venous access device in place. prior medication: allowed within 48 hours of study entry: * prophylactic antibiotics. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * critically ill or clinically unstable. * significant, active opportunistic or other infection requiring specific drug therapy at time of study entry. * ongoing iv alimentation. * uncorrected nutritional deficiencies that may contribute to anemia and/or leukopenia. * past history of or current evidence for any chronic hematologic disorder other than hemophilia a or b, anemia of chronic disease or anemia related to hiv infection. * malignancy likely to require systemic treatment during study. patients with the following are excluded: * critically ill, clinically unstable, or with concomitant diseases listed in patient exclusion co-existing conditions. * hypersensitivity to zidovudine (azt) or any other nucleoside analog. prior medication: excluded within 48 hours of study entry: * antibiotics. * excluded within 30 days of study entry: * antiretroviral agents other than zidovudine (azt). * acyclovir. * ganciclovir. * any investigational drug. * immunomodulating drugs. * cytolytic chemotherapeutic agents. * corticosteroids. * immunoglobulin preparations. * excluded within 4 months of study entry: * suramin. prior treatment: excluded within 6 months of study entry: * bone marrow transplantation. * excluded within 4 weeks of study entry: * lymphocyte transfusions. * radiation therapy.

Keywords: pilot projects neutropenia granulocyte-macrophage colony-stimulating factor acquired immunodeficiency syndrome zidovudine
ambient air pollution, preeclampsia, and preterm delivery

Conditions: Preeclampsia; Preterm Delivery

Summary: an epidemiologic study of pregnant women in western washington to measure the relationships between exposure to air pollutants and risks of preeclampsia and preterm delivery.

we will design models that use local traffic, weather, and population characteristics to predict monthly ambient concentrations of fine particulate matter (pm2.5) and carbon monoxide (co). these models will be used to estimate study participants' pm2.5 and co exposures during and before pregnancy. we will test whether these air pollutant exposures are associated with subsequent risk of preeclampsia and preterm delivery. additionally, we will test biological markers of maternal lipid peroxidation (thiobarbituric acid reactive substances) and inflammation (high sensitivity c-reactive protein) in maternal blood samples drawn during early pregnancy. we will also examine carboxyhemoglobin measured in early-pregnancy maternal blood samples as a marker of co exposure.

Eligibility criteria:
inclusion criteria: * english speaking * enrolled in parent study * pregnant at \<20 weeks gestation and attending prenatal care clinics affiliated with swedish medical center and tacoma general hospital exclusion criteria: -

Keywords: preeclampsia preterm delivery lipid peroxidation inflammation
extinction learning in youth with tourette syndrome

Conditions: Tourette Syndrome in Children; Tourette Syndrome in Adolescence; Habit Reversal Training; Tic

Summary: aversive sensory phenomena such as premonitory urges play a central role in the behavioral treatment model of tics. extinction learning and extinction recall are learning processes implicated within this model, but have not been directly evaluated in youth with tourette syndrome (ts). this study examines extinction learning and extinction recall in youth with ts using an experimental task. this study will also explore the relationship between extinction processes (i.e., extinction learning and extinction recall) and treatment outcomes with behavior therapy. findings from this investigation will be used to update the behavioral treatment model, which serves as the basis for evidence-based behavioral interventions.


Eligibility criteria:
youth with ts will be eligible for participation if they meet the following inclusion criteria: * age 8-17 years (inclusive) * have moderate tic severity or greater as evidenced by a ygtss total tic score greater than 13 (\>9 for youth with motor or vocal tics only) * have not received more than 4 previous sessions of hrt * be fluent in english. * medication free or on a stable dose of psychiatric medication for 8 weeks prior to enrollment. exclusion criteria for youth with ts: * an inability to complete rating scales * attend study visits.

Keywords: extinction learning behavior therapy tourette's disorder habit reversal training comprehensive behavioral intervention for tics
social and prognostic inequalities in patients hospitalised for cerebrovascular accident (cva) in four contrasting french departments

Conditions: Symptomatic CVA (de Novo CVA)

Summary: this study should also raise questions about the interest and feasibility of establishing a permanent registry of cva in the antilles and guyana. indeed in coming decades, the expected doubling of the population of persons aged over 60 years and the foreseeable changes in lifestyle will increase the burden of this disease, in particular since the region is marked by a high prevalence of arterial hypertension and diabetes and a high level of precarity. in addition, this study will provide epidemiological information on cva, its risk factors and management, which are non-existent for the department of french guyana where the health environment is manifestly insufficient. these data should make it possible to better evaluate the resources available and the healthcare needs in guyana.


Eligibility criteria:
inclusion criteria: * pre- inclusion * patients who have received information about the study (directly or via a person of trust), * patients aged more than 18 years, * patient hospitalised for a suspected first symptomatic cva (whatever the mechanism), preceded or not by a transient ischemic attack (tia), * patients with a cerebral imaging examination (ct-scan and/or mri), * in guyana, suspicion of a first cva according to who clinical criteria and who died before the authorised images for descriptive purposes, * patients able to answer questions personally or through a parent or a person of trust. definitive inclusion - patients with confirmed cva diagnosed according to clinical criteria (who criteria) and imaging criteria. exclusion criteria: * - patients who refuse to take part in the study, * patients with prior symptomatic cva, * patients without cerebral imaging (except in guyana, for patients with suspected cva who died before imaging), * patients with another severe evolutive disease that could cause death in the weeks following the cva, * patients who cannot be contacted by telephone at 1 month.
effect of adding mindfulness meditation to cognitive behavioral training on pain and quality of life in fibromyalgia

Conditions: Fibromyalgia

Summary: this study will be conducted to investigate the impact of adding mindfulness meditation to cognitive behavioral training on pain and quality of life in fibromyalgia.

fibromyalgia syndrome (fms) is a disorder characterized by chronic, widespread musculoskeletal pain. muscle and joint stiffness, insomnia, fatigue, mood disorders, cognitive dysfunction, anxiety, and generalized sensitivity are the main manifestations of this disease .cognitive-behavioral training presents as an important therapeutic resource, as it is capable of modifying patient's negative thoughts and expectations, improving mood, stress, coping with pain and problem solving, including behavioral interventions that specifically deal with improving the fibromyalgia symptoms (sleep hygiene, re-laxation training, activity rhythm).mindfulness meditation is the intentional effort to pay nonjudgmental attention to present-moment experiences and sustain this attention over time. the aim is to cultivate a stable and nonreactive present-moment awareness. mindfulness based pain management has been evaluated and showing significant positive changes in patients with chronic pain, with medium to large effect sizes on self-report measures of depression, positive outlook, pain acceptance. fifty women with fibromylagia will be assigned randomly to two groups; first one will receive mindfulness meditation for 30 minutes in addition to mobile application-based brain training program and the second one will receive mobile application-based brain training program alone

Eligibility criteria:
inclusion criteria: * confirmation of a clinical diagnosis of fibromyalgia by the patient's own physician. * wide spread pain for at least 3 months and tenderness at a minimum of 11of the 18 specific tender point sites. * age between 30 and 40 years. * female gender. * bmi: 25-30 kg/m2 exclusion criteria: * pregnancy * drug addicition * any current psychiatric disorder that would interfere with pro-gram adherence. * life-threatening disease

Keywords: mindfulness meditation cognitive behavioral training fibromyalgia
oral camostat compared with standard supportive care in mild-moderate covid-19 patients

Conditions: Covid19

Summary: this study will evaluate the efficacy of oral foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of sars-cov-2 virus in patients with mild-moderate covid-19 disease. patients will attend 4 study visits over a period of up to 28 days.


Eligibility criteria:
inclusion criteria: * diagnosis of covid-19 disease as presence of mild-moderate symptoms without signs of respiratory distress, with fda-cleared molecular diagnostic assay positive for sars-cov-2 within 72 hours prior to informed consent * males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication * females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication * females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy * females must have a negative pregnancy test at screening * participant agrees to maintain home or other quarantine as recommended by the study physician, except to visit the study site as required by the protocol exclusion criteria: * concomitant bacterial respiratory infection documented by respiratory culture. note: subjects on empirical antibiotic treatment for possible but unproven bacterial pneumonia, but who are positive for sars-cov-2, are allowed in the study. * previous use of antiviral drugs that may be active against covid-19. * abnormal laboratory test results at screening: * use of adrenocorticosteroids (except topical or inhaled preparations or oral preparations equivalent to or less than 10 mg of oral prednisone) or immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists or interleukin receptor blockers). note: treatment of study participants following institutional covid-19 treatment policies or guidelines, including the use of immunomodulatory medications, is permitted. this excludes treatment with agents that have the potential for direct antiviral activity, including convalescent plasma and no, and co-enrollment into other clinical studies that evaluate investigational agents for covid-19. * serious chronic disease (e.g., human immunodeficiency virus \[hiv\], cancer requiring chemotherapy within the preceding 6 months, and/or moderate or severe hepatic insufficiency). * previously received camostat mesilate within the past 30 days. * advanced kidney disease * advanced liver disease * history of alcohol or drug abuse in the previous 6 months. * psychiatric illness that is not well controlled (defined as stable on a regimen for more than one year). * taken another investigational drug within the past 30 days. * seemed by the investigator to be ineligible for any reason.
the effect of intradialytic exercise on the functional capacity of hemodialysis patients

Conditions: End Stage Kidney Disease

Summary: the purpose of this study is to explore the impact of an intradialytic exercise program on functional capacity, aerobic capacity, strength, quality of life, depression, hospitalizations and intradialytic episodes of hypotension. the investigators would also like to look at the impact of exercise training over twelve weeks on hemoglobin levels as well as the clearance of potassium, phosphate and urea. our hypothesis is that the above mentioned outcomes will positively improve over the twelve week intervention.


Eligibility criteria:
inclusion criteria: * cardiac and hemodynamic stability * absence of severe musculoskeletal impairment * increased musculoskeletal weakness * vital signs within normal range for exercise * desire/motivated to exercise * clearance from nephrologist and kinesiologist exclusion criteria: * compromised cardiac profiles * hemodynamic instability * severe bone disease * medical conditions which contraindicate exercise

Keywords: intradialytic exercise hemodialysis
clinical trial of csmed wound dressing for radiation dermatitis

Conditions: Radiation Dermatitis

Summary: investigate the effects of csmed® for preventing and managing radiation dermatitis in patients with breast cancer and head-neck cancer receiving radiotherapy (≥50 gy).

a prospective study was conducted at the university hospital medical center. the patient received part of the breast/neck skin csmed® dressing or clinical routine skin care. record the difference between the part of the skin with dressing and undressed skin for each patient. the severity of acute radiation dermatitis was graded using the rtog clinical scoring standard. from the beginning of the treatment to 4 weeks after the end of the treatment, skin pain, itching, local fever and tightness, as well as skin healing time were collected every week.

Eligibility criteria:
inclusion criteria: * patients receiving radiation therapy (including undamaged skin and rtog grade 1 dermatitis). * patients who voluntarily agree to participate in the trial and sign the subject's consent form. exclusion criteria: * patients with dermatitis and burns not caused by radiation therapy. * involuntary patients without signed consent. * those who are allergic to the ingredients in this product.
a study of cdpath™ to help manage and treat crohn's disease

Conditions: Crohn's Disease

Summary: cdpath™ is a tool to help predict the potential for developing crohn's disease related complications in certain adult participants within 3 years. the main aim of the study is to explore the use of cdpath™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their crohn's disease. the number of visits will be decided by the study clinic according to their standard practice.

the tool being tested in this study is called cdpath™. cdpath™ is being used to provide a graphical representation of an individual participant's risk of developing a cd-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have cd. this study will gather data on the use of the tool in real-world settings to inform practical use of cdpath™. the study will enroll approximately 200 patients. participants and health care providers (hcps) will be surveyed to understand their satisfaction with the cdpath™ process and with their treatment choice. this multi-center trial will be conducted in the united states. the overall time to participate in this study is 36 months. participants will make multiple visits to the hcp's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.

Eligibility criteria:
inclusion criteria: 1. has an initial diagnosis of cd established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available). 2. has agreed to use the cdpath™ tool. 3. has reliable access to the internet and is willing to answer electronic patient-reported outcomes (epros) throughout the study. exclusion criteria: 1. has had known complications from cd including but not limited to: bowel stricture, cd-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. a perianal fistula or abscess without other signs of penetrating disease is allowed. 2. has had any non-cd-related abdominal surgery. 3. has received investigational biologic or nonbiologic agents for the treatment of cd in an investigational protocol. approved biologic or nonbiologic agents for cd are allowed. 4. has previously used cdpath™ or prospect results to assess cd risk for complications.

Keywords: drug therapy